Presentations

BioCardia Corporate Presentation
The Science of CardiAMP Cell Therapy
BioCardia Presentation at Forum for Innovative Regenerative Medicine (Tokyo, Japan)
Meeting on the Mesa "Successful Strategies in the Design and Delivery of a Cell/Gene Therapy Clinical Development Program"

Events

October 2019

Date: October 28-29, 2019
Location: Jupiter, FL
Event: Dawson James Securities 5th Annual Small Cap Growth Conference
To register and view a LIVE broadcast, click here

May 2019

Date: May 8-11, 2019
Location: San Francisco, CA
Event: 40th Annual Heart Rhythm Society Scientific Sessions

March 2019

Date: March 21, 2019
Location: New York, NY
Event: Cell & Gene Therapy Investor Day

January 2019

Date: January 7-10, 2019
Location: San Francisco, CA
Event: JP Morgan Healthcare Conference

November 2018

Date: November 12, 2018
Location: Chicago, IL
Event: American Heart Association Scientific Sessions 2018 Conference
Title: "The CardiAMP Heart Failure Trial: Efficacy Outcomes from Roll-In Phase"

October 2018

Date: October 3, 2018
Location: La Jolla, CA
Event: 2018 Cell & Gene Meeting on the Mesa
Title: "Successful Strategies in the Design and Delivery of a Cell/Gene Therapy Clinical Development Program"

Date: October 5, 2018
Location: Houston, TX
Event: 2018 Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine
Title: "The CardiAMP Heart Failure Trial"

September 2018
Date: September 24, 2018
Location: San Diego, CA
Event: 2018 Transcatheter Cardiovascular Therapeutics Conference
Title: "The CardiAMP Heart Failure Study: First Results from Unblinded Roll-In Phase"

Date: September 24, 2018
Location: San Diego, CA
Event: 2018 Transcatheter Cardiovascular Therapeutics Conference
Title: "Performance of Helix Transendocardial Biotherapeutic Delivery System after 300 Cases"



News


Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.